Trial NCT01633060

View at ClinicalTrials.gov 
Org. Study IDs: CBKM120F2303
Secondary IDs: 2012-002571-34

Last trial update was posted on 2019-01-30

MeSH Interventions

Fulvestrant

MeSH Conditions

Breast Neoplasms

Other Conditions

Metastatic Breast Cancer

Stopping Reasons

Novartis decided not to pursue further development of buparlisib program (assessment of moderate PFS benefit with know, but manageable, buparlisib profile).

Limitations And Caveats

The primary efficacy analysis was completed by 23May16 (primary PFS analysis cutoff date). The study was later terminated and the final safety analysis was conducted up to 08Sep17. One CRF was collecting on 21Sep2017 for survival follow up (LPLV).

Result Publications

N/A

Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID